Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
|Videos|December 25, 2020
A Recommended Plan for Those Struggling with Substance Abuse During the Holidays
Pharmacy Times spoke with Jeremy Barnett, LMHC, CASAC & Expert at Help.org, about recommended plans and advice for those who are struggling with addiction during the holidays and the COVID-19 pandemic.
Advertisement
Pharmacy Times spoke with Jeremy Barnett, LMHC, CASAC & Expert at Help.org, about recommended plans and advice for those who are struggling with addiction during the holidays and the COVID-19 pandemic.
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
3
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
4
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
5